Larkspur Biosciences
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Larkspur Biosciences - overview
Established
2020
Location
Watertown, MA, US
Primary Industry
Biotechnology
About
Based in the US, and founded in 2020, Larkspur Biosciences operates as a biotechnology business that is working to develop the next generation of precision immunotherapies to combat cancer. In May 2023, Larkspur Biosciences raised USD 17. 55 million in series A funding co-led by new investors 3E Bioventures Capital, Polaris Partners and Takeda Ventures, with participation from other new investors Cornell University Endowment, Creacion Ventures and MED-FINE Capital. Larkspur Biosciences specializes in the development of immunotherapies that aid in the treatment of cancer.
The company provides immunotherapy solutions that are tailored to specific patient populations based on molecular definitions, and they target the critical interface between the tumor and the immune system. This method enables patients, including those with colorectal cancer (CRC) and other diseases, to mount a powerful and long-lasting immune response. The company plans to use the May 2023 funding to support R&D, focus on IND-enabling studies for its lead program and the ongoing preclinical studies for its program targeting Pin1 to develop therapies for the treatment of colorectal cancer.
Current Investors
Polaris Partners, Cornell University Endowment, Takeda Ventures
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Website
www.larkspur.bio
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.